Clinical relevance of alternative splicing

Indian Journal of Human Genetics

Volumn 12, Issue 2, 2006, Pages 45-52

  Ravindra, T ^a   Lakshmi, N K ^a   Chaitanya, K ^a   Surender, V ^a   Ahuja, Y R ^b  

^a Bhavans New Science College   (India)

^b Vasavi Medical and Research Centre   (India)

Author keywords

Aberrant splice variant; Alternative splicing; Antisense oligonucleotides; Expressed sequence tag; Microarrays

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRCA1 PROTEIN; BRCA2 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FOMIVIRSEN; GENE PRODUCT; GENOMIC DNA; HERMES ANTIGEN; MESSENGER RNA; OLIGONUCLEOTIDE; POTASSIUM CHANNEL; PROTEIN; PROTEIN BCL X; PROTEIN FTDP 17; PROTEIN IGHD II; PROTEIN P73; PROTEIN PRPF 31; PROTEIN TRX 1; PROTEIN WT1; PROTEIN XPG; RIBONUCLEOPROTEIN; SURVIVAL MOTOR NEURON PROTEIN; TAU PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE RNA SPLICING; CARCINOGENESIS; COMPUTER PROGRAM; DNA MICROARRAY; EXON; GENE EXPRESSION; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HUMAN GENOME PROJECT; MALIGNANT NEOPLASTIC DISEASE; PHARMACOGENOMICS; PREDICTION; PROTEOMICS; QUALITATIVE ANALYSIS; REVIEW; RNA TRANSCRIPTION; TUMOR GROWTH;

EID: 33750083914     PISSN: 09716866     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-6866.27786     Document Type: Review

References (77)

1. International human genome sequencing consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-45.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
3. Venter JC, Adams MW, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51.
4. Graveley BR. Alternative splicing: Increasing diversity in the proteomic world. Trends Genet 2001;17:100-7.
5. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002;30:13-9.
6. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, et al. Differential sub-cellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-D11b. Oncogene 1997;14:1-16.
7. Henke W, Loening SA. Recently, betaine has been introduced as an additive in different PCR strategies. Nucleic Acid Res 1998;26:687.
8. Zolezzi F, Valli M, Clementi M, Mammi I, Cetta G, Pignatti PF, et al. Mutation producing alternative splicing of exon 26 in the COL1A2 gene causes type IV osteogenesis imperfecta with intrafamilial clinical variability. Am J Med Genet 1997;71:366-70.
9. Mottes JR, Iverson LE. Tissue-specific alternative splicing of hybrid Shaker/lacZ genes correlates with kinetics difference in Shaker K+ currents in vivo. Neuron 1995;14:613-23.
10. Jing ZH, Wu JY. Alternative splicing and programmed cell death. Proc Soc Exp Biol Med 1999;220:64-72.
11. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003;17:419-37.
12. Lopez AJ. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation. Ann Rev Genet 1998;32:279-305.
13. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in messenger RNA splice junctions of human genes: Causes and consequences. Hum Genet 1992;90:41-54.
14. Jin W, McCutcheon IE, Fuller GN, Huang ES, Cote GJ. Fiboblast growth factor receptor -1 alpha-exon exclusion and polyprimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res 2000;60:1221-4.
15. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. BCL-X, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
16. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fiboblast growth factor receptor 2 (FGFR2) in human prostate cancer. Oncogene 1997;15:3059-65.
17. Xie J, Black DL. A CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels. Nature 2001;410:936-9.
18. Lee MP, Feinberg AP. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997;57:3131-4.
19. Hartmann AM, Nayler O, Schwaiger FW, Obermeier A, Stamm S. The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn). Mol Biol Cell 1999;10:3909-26.
20. Coward E, Haas S, Vingron M. SpliceNest3 visualization of gene structure and alternative splicing based on EST clusters. Trend Genetics 2003;18.
21. Boguski MS, Schuler GD. Establishing a human transcript map. Nat Genet 1995;10:369-71.
22. Beaudoing E, Gautheret D. Identification of alternate polyadenylation sites and analysis of their tissue distribution using EST data. Genome Res 2001;11:1520-6.
23. Schmitt AO, Specht T, Beckmann G, Dahl E, Pilarsky CP, Hinzmann B, et al. Exhaustive mining of EST libraries for genes differentially expressed in normal and tumor tissues. Nucleic Acid Res 1999;27:4251-60.
24. Bortoluzzi S, d'Alessi F, Romualdi C, Danieli GA. The human adult skeletal muscle transcriptional profile reconstructed by a novel computational approach. Genome Res 2000;10:344-9.
25. Xie H, Zhu W, Wasserman A, Grebinskiy V, Olson A, Mintz L. Computational analysis of alternative splicing using EST tissue information. Genomics 2002;80:326-30.
26. Sorek R, Amitai M. Piecing together the significance of splicing. Nat Biotechnol 2001;19:196.
27. Kan Z, Rouchka EC, Gish WR, States DJ. Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res 2001;11:889-900.
28. Cochet O, Heard DJ, Fehlbaum P, Ducray C, Bracco L. Exploiting human genomic diversity through alternative RNA splicing. Pharmacogenomics 2003;26-36.
29. Schweighoffer, F. Ait-Ikhlef A, Resink AL, Brinkman B, Melle-Milovanovic D, Laurent-Puig P, et al. Qualitative gene profiling: A novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity. Pharmacogenomics 2000;1:187-97.
30. Lee C, Atanelov L, Modrek B, Xing Y. ASAP: The alternative splicing annotation project. Nucleic Acids Res 2003;31:101-5.
31. Clark TA, Sugnet CW, Ares M. Jr. Genomewide analysis of mRNA processing in Yeast using Splicing-specific microarrays. Science 2002;296:907-10.
32. Peng WT, Robinson MD, Mnaimneh S, Krogan NJ, Cagney G, Morris Q, et al. A panoramic view of yeast non-coding RNA processing. Cell 2003;113:919-33.
33. Yeakley JM, Fan JB, Doucet D, Luo L, Wickham E, Ye Z, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002;20:353-8.
34. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003;301:836-8.
35. Hu GK, Madore SJ, Moldover B, Jatkoe T, Balaban D, Thomas J, et al. Predicting splice variant from DNA expression data. Genome Res 2001;11:1237-45.
36. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Lorench PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302:2141-4.
37. Wang A, Forman-Kay J, Luo Y, Luo M, Chow YH, Plumb J, et al. Identification and characterization of human genes encoding Hprp3p and Hprp4p, interacting components of the spliceosome. Hum Mol Genet 1997;6:2117-26.
38. Huang X, Li J, Lu L, Xu M, Xiao J, Yin L, et al. Novel development-related alternative splices in human testis identified by cDNA microarrays. J Androl 2005;26:189-96.
39. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-beta1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000;97:9618-23.
40. Nissim-Rafinia M, Chiba-Falek O, Sharon G, Boss A, Kerem B. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000;9:1771-8.
41. Kalbfuss, B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporial dementia and Parkinsonism linked to chromosome 17. J Biol Chem 2001;276:49286-93.
42. Mercatante DR, Kole R. Control of alternative splicing by antisense oligonucleotides as potential chemotherapy: Effect on gene expression. Biochem Biophys Acta 2002;1587:126-32.
43. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: Basic principles and recent applications. Nat Rev Drug Discov 2002;1:503-14.
44. Pilch B, Allemand E, Facompre M, Bailly C, Riou JF, Soret J, et al. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly and splicing by the antitumor drug NB-506. Cancer Res 2001;61:6876-84.
45. Varania L, Spillantini MG, Goedert M, Varani G. Structural basis for recognition of the RNA major groove in the tau exon 10 splcing regulatory element by aminoglycoside antibiotics. Nucleic Acid Res 2000;28:710-9.
46. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Gent 2001;10:2841-9.
47. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosi airway epithelia by splicesome-mediated RNA trans-splicing. Nat Biotechnol 2002;20:47-52.
48. Levanon EY, Sorek R. The importance of alternative splicing in the drug discovery process. Targets 2003;2:109-14.
49. Kurreck J. Antisense technologies- Improvement through chemical modifications. Eur J Biochem 2003;270:1628-44.
50. Herdewijn P. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev 2000;10:297-310.
51. Zon G. History of antisense drug delivery. In antisense research and applications; Crooke S, Le Bleu B editors; CRC Press Inc: Boca Raton; 1993. p. 1-3.
52. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001;6:303-15.
53. Crooke ST. Progress in antisense technology: The end of the beginning. Methods Enzymol 2000;313:3-45.
54. Marwick C. First "antisense" drug will treat CMV retinitis. JAMA 1998;280:871.
55. Kawamoto S, Yoshii J, Mizuno K, Ito K, Miyamoto Y, Ohnishi T, et al. BodyMap: A Collection of 3′ ESTs for analysis of human gene expression information. Genome Res 2000;10:1817-27.
56. Cogan JD, Prince MA, Lekhakula S, Bundey S, Futrakul A, McCarthy EM, et al. A novel mechanism of aberrant pre-mRNA splicing in humans. Hum Mol Genet 1997;6:909-12.
57. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
58. Orban TI, Olah E. Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun 2001;280:32-8.
59. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, et al. Restoration of hemoglobin a synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 2000;97:9591-6.
60. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
61. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg) m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998;101:487-96.
62. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time light cycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-68.
63. Wang J, Pegoraro E, Menegazzo E, Gennarelli M, Hoop RC, Angelini C, et al. Myotonic dystrophy: Evidence for a possible dominant-negative RNA mutation. Hum Mol Genet 1995;4:599-606.
64. Herrera-Gayol A, Jothy S. Adhesion proteins in the biology of breast cancer: Contribution of CD44. Exp Mol Pathol 1999;66:149-56.
65. Wittig BM, Goebel R, Weg-Remers S, Pistorius G, Feifel G, Zeitz M, et al. Stage-specific alternative splicing of CD44 and alpha 6 beta 1 integrin in colorectal tumorigenesis. Exp Mol Pathol 2001;70:96-102.
66. Sneath, RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998;51:191-200.
67. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-72.
68. Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 2000;60:4049-52.
69. Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T. Identification of novel alternative splicing of human FGF receptor 4: Soluble- form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 2000;267:658-62.
70. Bieche I, Lidereau R. Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. Cancer Res 1999;59:2546-50.
71. Cheng L, Spitz MR. Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: A case-control analysis. Carcinogenesis 2000;21:1527-30.
72. Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, Yokoi T, et al. Human neuroblastomas with unfavourable biologies express high levels of brain derived neurotropic factor mRNA and a variety of its variants. Cancer Lett 2001;164:51-60.
73. Mercatante DR, Sazani P, Kole R. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets 2001;1:211-30.
74. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, et al. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001;20:514-22.
75. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
76. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-Cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994;1218:292-6.
77. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459-66.